HALO
Halozyme Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Halozyme Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
Halozyme Therapeutics, Inc.
130.89
−0.29 · −0.22%
post 130.16 −0.56%
Fund move
Fund move
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | BlackRockBlackRockindex-like | $1.0B | 10.70% | +0.05% | |
| 2 | Vanguard Capital ManagementVanguardindex-like | $418.8M | 4.32% | +1.52% | |
| 3 | Vanguard Portfolio ManagementVanguard Portfolioindex-like | $414.8M | 4.27% | +0.95% | |
| 4 | State StreetState Streetindex-like | $405.4M | 4.18% | +4.89% | |
| 5 | InvescoInvesco | $248.7M | 2.56% | −20.80% | |
| 6 | Morgan StanleyMorgan Stanley | $221.7M | 2.28% | +10.55% | |
| 7 | Boston PartnersBoston Partners | $216.8M | 2.23% | +3.35% | |
| 8 | Bank of AmericaBank of America | $214.5M | 2.21% | −5.92% | |
| 9 | Geode Capital ManagementGeodeindex-like | $197.3M | 2.03% | +0.57% | |
| 10 | William Blair Investment ManagementWilliam Blair | $196.5M | 2.03% | −0.59% | |
| 11 | Snyder Capital Management L PSnyder Capital Management L P | $187.5M | 1.93% | +3.14% | |
| 12 | Dimensional Fund AdvisorsDimensional | $163.5M | 1.69% | +0.47% | |
| 13 | D. E. ShawD. E. Shaw | $160.0M | 1.65% | +7.64% | |
| 14 | LOS Angeles Capital Management & Equity ResearchLOS Angeles Capital Management & Equity Research | $151.7M | 1.56% | +180.91% | |
| 15 | Royal London Asset ManagementRoyal London | $141.7M | 1.46% | +12.43% | |
| 16 | Arrowstreet Capital, Limited PartnershipArrowstreet Capital, Limited Partnership | $133.4M | 1.37% | −11.13% | |
| 17 | AlliancebernsteinAlliancebernstein | $132.8M | 1.37% | −2.30% | |
| 18 | Two Sigma InvestmentsTwo Sigma | $129.4M | 1.33% | +4.31% | |
| 19 | UBS GroupUBS | $116.8M | 1.20% | +63.26% | |
| 20 | Fuller & Thaler Asset ManagementFuller & Thaler | $116.7M | 1.20% | +1.76% | |
| 21 | Norges BankNorges Bankindex-like | $116.1M | 1.20% | — | |
| 22 | First Trust AdvisorsFirst Trust | $110.9M | 1.14% | −4.40% | |
| 23 | LSV Asset ManagementLSV | $110.4M | 1.14% | +2.82% | |
| 24 | Stephens Investment Management GroupStephens | $109.0M | 1.12% | +14.29% | |
| 25 | Wells FargoWells Fargo | $108.8M | 1.12% | −9.46% |
675 managers report $9.7B of Halozyme Therapeutics on form 13F for the quarter ended Jun 30 '26. 58 of them hold 80% of it; BlackRock is largest at 10.70%.
Linked news
Expected move
Inputsstraddle ±7.6%
spot 130.91exp Nov 20ATM strike 130ATM straddle 11.70IV 47%